Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis

María Teruel1*, Carmen P Simeon2, Jasper Broen3, Madelon C Vonk3, Patricia Carreira4, Maria Teresa Camps5, Rosa García-Portales6, Esmeralda Delgado-Frias7, Maria Gallego8, Gerard Espinosa9, the Spanish Scleroderma Group10, Lorenzo Beretta11, Paolo Airó12, Claudio Lunardi13, Gabriela Riemekasten14, Torsten Witte15, Thomas Krieg16, Alexander Kreuter17, Jörg HW Distler18, Nicolas Hunzelmann16, Bobby P Koeleman19, Alexandre E Voskuyl20, Annemie J Schuerwegh21, Miguel Ángel González-Gay22, Timothy RDJ Radstake23 and Javier Martin1

Abstract

Introduction: The aim of the present study was to investigate the possible role of CD40 and CD40 ligand (CD40LG) genes in the susceptibility and phenotype expression of systemic sclerosis (SSc).

Methods: In total, 2,670 SSc patients and 3,245 healthy individuals from four European populations (Spain, Germany, The Netherlands, and Italy) were included in the study. Five single-nucleotide polymorphisms (SNPs) of CD40 (rs1883832, rs4810485, rs1535045) and CD40LG (rs3092952, rs3092920) were genotyped by using a predesigned TaqMan allele-discrimination assay technology. Meta-analysis was assessed to determine whether an association exists between the genetic variants and SSc or its main clinical subtypes.

Results: No evidence of association between CD40 and CD40LG genes variants and susceptibility to SSc was observed. Similarly, no significant statistical differences were observed when SSc patients were stratified by the clinical subtypes, the serologic features, and pulmonary fibrosis.

Conclusions: Our results do not suggest an important role of CD40 and CD40LG gene polymorphisms in the susceptibility to or clinical expression of SSc.

Introduction

Systemic sclerosis (SSc) is an autoimmune disease of the connective tissue characterized by excessive fibrosis of the dermis and vascular damage. It also affects internal organs, such as the lung, gastrointestinal, and vascular systems [1]. SSc is a complex polygenic disease in which environmental and genetic factors are involved in the susceptibility to this disease. Candidate gene and genome-wide association studies (GWASs) performed in SSc have identified new loci implicated in the susceptibility to SSc [2]. Nevertheless, the complete genetic components of SSc remain unknown.

CD40 is a member of the tumor necrosis factor receptor superfamily (TNFR), and it is expressed on the surface of several immune and nonhematopoietic cells, such as B cells, macrophages, dendritic cells, fibroblasts, and endothelial cells in certain pathogenic conditions [3]. Its ligand, CD40LG (CD154), is expressed mainly on the surface of CD4+ T cells. CD40-CD40LG interactions are necessary for the activation of both humoral and cellular immune responses [3]. The CD40-CD40LG pathway has been suggested to play an important role in the pathogenesis of autoimmune diseases [4]. An increase of soluble CD40LG (sCD40LG) has been observed in many autoimmune diseases, such as systemic lupus erythematosus (SLE) [5], rheumatoid arthritis (RA) [6], and Graves disease (GD) [7]. Interestingly, patients with SSc and limited cutaneous disease have higher levels of...
sCD40LG in the plasma than those of the diffuse cutaneous disease [8]. Similarly, high levels of CD40 protein were observed in both the plasma [9] and the cell surface of skin fibroblasts [10] from SSc patients. In addition, previous studies reported the association of CD40 polymorphisms with susceptibility to a number of autoimmune diseases, such as GD [11], multiple sclerosis [12], RA [13,14], Crohn disease [15], and with visual ischemic manifestations in individuals with biopsy-proven giant cell arteritis [16]. Nevertheless, in the case of SLE, contradictory data exist [17-19]. In addition, mutations of CD40LG were observed in patients with the hyper-immunoglobulin M (IgM) syndrome [20], and genetic variations located at the 3UTR of the CD40LG gene were associated with two autoimmune diseases, SLE [21] and RA [22].

Taking into account these considerations, we aimed to investigate the potential association of CD40 and CD40LG genes polymorphism with SSc.

Materials and methods

Patients

In total, 2,670 SSc patients and 3,245 healthy individuals from four European populations were included in this study (Spain: cases, 1,103; controls, 1,610; Germany: cases, 554; controls, 437; The Netherlands: cases, 380; controls, 489; Italy: cases, 633; controls, 709). All the patients fulfilled the 1980 American College of Rheumatology (ACR) classification criteria for SSc [23]. Limited cutaneous disease (lcSSc) was defined as definite skin thickening confined to the knees and elbow [24,25]. Measurement of main SSc-specific autoantibodies, anti-centromere antibodies (ACAs), and antitopoisomerase I antibodies (ATAs), was performed by using standard methods. Pulmonary fibrosis data were investigated by using a computed tomography scan. The main features of all populations included in this study were previously reported [26-28].

Patients and controls were included in the study after written informed consent, according to the declaration of Helsinki. The study was approved by local ethical committees from all the participating centers.

SNPs selection and genotyping

DNA from patients and controls was obtained by using standard methods. CD40 is located on chromosome 20q13.12. Three single-nucleotide polymorphisms (SNPs) of CD40 associated with other autoimmune diseases were selected. rs1883832 had been associated with GD [11]; whereas rs4810485, in linkage disequilibrium with rs1883832 ($r^2 = 0.95$), has been identified as a new risk factor for RA [13]. Furthermore, rs1535045 has been associated with subclinical atherosclerosis in diabetes families [29]. CD40LG is found on chromosome Xq26.3. Two genetic variants located in 5 UTR (rs3092952) and 3 UTR (rs3092920) of CD40LG ($r^2 = 0.38$) were selected. These SNPs are located in different haplotype blocks of CD40LG [17]. The variant rs3092920 is located near the 3 UTR microsatellite, which was previously associated with RA and SLE [21,22]; whereas rs3092952 is a functional variant related to the levels of sCD40LG in plasma [30].

All SNPs were genotyped in the same center by using a TaqMan SNP genotyping assay in a 7900HT Real-Time polymerase chain reaction (PCR) system, by following the conditions recommended by the manufacturer (Applied Biosystems, Foster City, CA, USA). About 10% of the patients were genotyped twice to verify the genotyping consistency, showing 99% identical genotypes. The genotyping call-rate success was >95% for both cases and controls in all populations.

Statistical analysis

The Hardy-Weinberg equilibrium (HWE) was tested by means of the Fisher Exact test or $\chi^2$ when necessary. The case-control association study was performed by using a $2 \times 2$ contingency table with $\chi^2$ to obtain P values, odds ratios (ORs), and 95% confidence intervals (CIs). Combined OR was calculated according to a fixed-effects model (Mantel-Haenszel meta-analysis), and the heterogeneity of OR among all populations was calculated by using the Breslow-Day test. P values <0.05 were considered statistically significant. Statistical analyses were carried out with PLINK [31].

The estimation of the power of the study to detect an effect of a polymorphism in disease susceptibility was performed by using The CaTS Power Calculator software [32].

Results

CD40 gene variants in SSc

Three CD40 polymorphisms were genotyped in four European populations. First, we analyzed the cohorts individually and then combined the samples in a pooled analysis. Table 1 describes allelic distribution of the three SNPs in the pooled analysis, and Additional file 1, Table S1-3 contains detailed data for each population. Both cases and controls were confirmed to be in HWE in all populations. No evidence of association between CD40 polymorphisms and susceptibility to SSc was observed in the pooled analysis (allelic P value rs1883832: $P = 0.61$; OR, 1.02; 95% CI, 0.94 to 1.11; rs4810485: $P = 0.42$; OR, 1.04; 95% CI, 0.95 to 1.13; rs1535045: $P = 0.275$; OR, 0.95; 95% CI, 0.88 to 1.04).

To investigate the possible influence of the CD40 polymorphisms with clinical features, we stratified the
patients according to the main SSc manifestations. However, we did not observe evidence of association after comparing lcSSc and dcSSc with healthy subjects (see Table 1). Additionally, we compared the presence of SSc-specific autoantibodies in the patients with the healthy individuals, but no significant differences were observed (Table 1). Likewise, no significant association was observed when patients with pulmonary fibrosis were compared with healthy controls (Table 1).

**CD40LG gene variants in SSc**

Because **CD40LG** is located on the X-chromosome and shows the sexual bias of this disease, we performed the analysis separately for each gender. Table 2 shows the allelic frequencies in SSc females of the two **CD40LG** polymorphisms in the pooled analysis, and Additional file 1, Table S4-5 shows the frequencies for each population. Deviations from HWE were not observed. With the Mantel-Haenszel test, the genotype and allele frequencies were similar between SSc patients and healthy individuals (allelic $P$ value rs3092952: $P = 0.44$; OR, 0.96; 95% CI, 0.85 to 1.07; rs3092920: $P = 0.565$; OR, 0.96; 95% CI, 0.83 to 1.11). No statistical differences were observed when SSc patients were stratified by common subtype of the disease, the presence of SSc-specific autoantibodies, and pulmonary fibrosis (Table 2).

In addition, we analyzed these two polymorphisms in SSc male patients, but no evidence of association was found in the combined analyses (see Additional file 1, Table S6-7). However, these results should be interpreted with caution because the statistical power is insufficient to detect association because of low sample size.

**Discussion**

The important role of the CD40-CD40LG pathway in autoimmunity [4], together with the association of the CD40 gene with a number of autoimmune diseases, prompted us to investigate for the first time the contribution of **CD40** and **CD40LG** genes in SSc.

Despite the previous findings [8-10], we observed no evidence of association of the **CD40** or **CD40LG** gene variants analyzed with SSc. It was also the case when SSc patients were stratified by the SSc clinical subtypes, specific autoantibodies, or pulmonary fibrosis. We analyzed a large European population from four different countries to increase the robustness of the study. In this regard, our combined study had an estimated power of 92% to detect the relative risk, with OR of 1.15 obtained for RA susceptibility [13,14], at the 5% significance level. Therefore, it seems unlikely that the absence of association found in our study would be due to Type II error.

---

**Table 1 Pooled analysis of CD40 polymorphisms**

| SNP  | Change | Samples set | $N$ | Minor allele, no. (frequency) | $P$ value | OR [95% CI] | $P$-BD |
|------|--------|-------------|-----|-------------------------------|-----------|-------------|--------|
| rs1883832 | T/C | Controls | 3,138 | 1,427 (0.277) | 0.610 | 1.02 [0.94-1.11] | 0.904 |
| SSc  | 2,605 | 1,424 (0.274) | 0.246 | 1.06 [0.96-1.16] | 0.496 |
| lcSSc | 1,758 | 987 (0.276) | 0.683 | 0.97 [0.86-1.10] | 0.446 |
| dcSSc | 860 | 451 (0.271) | 0.879 | 1.01 [0.90-1.13] | 0.355 |
| ACA + | 1,077 | 592 (0.261) | 0.108 | 1.11 [0.98-1.26] | 0.946 |
| ATA + | 716 | 416 (0.293) | 0.433 | 1.05 [0.92-1.20] | 0.802 |
| Pulmonary fibrosis | 702 | 394 (0.278) | 0.955 | 1.09 [0.99-1.20] | 0.308 |

| rs4810485 | G/T | Controls | 3,122 | 1,652 (0.272) | 0.420 | 1.04 [0.95-1.13] | 0.935 |
| SSc  | 2,560 | 1,388 (0.274) | 0.155 | 1.07 [0.97-1.18] | 0.481 |
| lcSSc | 1,736 | 967 (0.277) | 0.817 | 0.99 [0.87-1.12] | 0.600 |
| dcSSc | 839 | 436 (0.269) | 0.844 | 1.01 [0.90-1.13] | 0.399 |
| ACA + | 1,071 | 580 (0.257) | 0.080 | 1.12 [0.99-1.28] | 0.890 |
| ATA + | 699 | 402 (0.292) | 0.983 | 1.05 [0.92-1.20] | 0.605 |
| Pulmonary fibrosis | 682 | 375 (0.272) | 0.976 | 1.03 [0.90-1.18] | 0.028 |

Controls are used as reference for all comparisons. All $P$ values have been calculated for the allelic model by using the Mantel-Haenszel test under fixed effect. $P$-BD, $P$ value by the Breslow-Day method.
In the present study, we analyzed the functional CD40-1C/T polymorphism (rs1883832). This genetic variant is located at -1 from the ATG, within a Kozak sequence, a stretch of nucleotides essential for translation that flanks the start codon in vertebrate genes [33]. The presence of a major allele (C) in this SNP is associated with the increase of the efficiency of CD40 translations [11]. Although quantitative differences between CD40 mRNA and proteins have been observed in SSc skin fibroblasts [10], the absence of association found for rs1883832 suggests that this variant might not affect the translation of CD40 mRNA. This process may be upregulated in these abnormal skin fibroblasts, or other genes of the CD40 signaling pathway may influence the CD40 expression. However, functional studies in this way should be constructed before excluding an association between this variant and the CD40 expression in SSc.

Although CD40 might be a common susceptibility locus for some autoimmune diseases [11-16], our results do not suggest an important role of CD40 in the susceptibility to SSc. Several genes have been recently disclosed to play a function in the susceptibility to autoimmune diseases, suggesting that these diseases share a genetic background [34]. However, these loci may not be universal genetic factors for autoimmune disorders; therefore, the autoimmunity might result from specific and multiple pleiotropic effects [19]. Also, other genes are unique for each disease, reflecting a specific etiology [19,34]. Additional studies are required for the identification of specific and shared genetic pathways that contribute to a better understanding of the pathogenesis of the autoimmune diseases.

The role of the CD40LG in the susceptibility to autoimmune diseases has not been investigated as broadly as that of CD40, mainly because this gene is located on the X chromosome. The different prevalences of these diseases in both genders can suggest that genes located on the X chromosome could be susceptibility factors in autoimmune diseases; however, few studies analyzed polymorphisms on this chromosome. Mutations on this gene are associated with X-linked hyper-IgM syndrome, a familial genetic disorder characterized by an increase of IgM level and a decrease of IgG and IgA [20], but in SLE, no evidence of association has been found [17]. Similarly, our results show that the CD40LG gene may not be SSc susceptibility loci.

Conclusions

Our results do not suggest an important role of CD40 and CD40LG genes in the susceptibility to SSc. Additional studies are required to draw firm conclusions about the exact role of the CD40 and CD40LG genes in SSc susceptibility because other variants might be involved in SSc. Future studies involving other genes of the CD40-CD40LG pathway should be conducted to elucidate fully the contribution of this pathway in the pathogenesis of SSc.

Additional material

Additional file 1: Supplementary Tables 1 through 7. Genotype and allele distribution of the CD40 and CD40LG polymorphisms for each population included in the current study.

Abbreviations

ACA: anti-centromere antibody; ATA: anti-topoisomerase I antibody; CI: confidence interval; dcSSc: diffuse cutaneous subtype; GD: Graves disease;
GWAS: genome-wide association study; HWE: Hardy-Weinberg equilibrium; lC5Sc: limited cutaneous subtype; OR: odds ratio; P-BD: P value by Breslow-Day method; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SNP: single-nucleotide polymorphism; SSc: systemic sclerosis.

Acknowledgements

We thank Sofia Vargas, Sonia Garcia, and Gema Robledo for their excellent technical assistance, and all the patients and healthy controls for kindly accepting their essential collaboration. We thank Banco Nacional de ADN (University of Salamanca; Spain) for supplying part of the control material. We also thank EUSTAR (The EU-LAR Scleroderma Trials and Research Group) and the German Network of Systemic Sclerosis for the facilitation of this project.

This work was supported by the following grants. JM was funded by SAF2009-11110 from the Spanish Ministry of Science, byCTS-4977 and PI-0990-2010 from Junta de Andalucía, and by RETICS Program, RD08/0075 (RIER) from Instituto de Salud Carlos III ( ISCIII), within the VI PN de I+D+i 2008-2011 (FEDER). T.R.D.J.R was funded by the VDI laureate from the Dutch Association of Research (NWO) and Dutch Arthritis Foundation (National ReumaFonds). JM and TRDJR were sponsored by the Orphan Disease Program grant from the European League Against Rheumatism (EULAR). TW was awarded grants by DFG WI 1031/6-1 and DFG KFO 250 T10P. MT was supported by Spanish Ministry of Science through the program Juan de la Cierva (JCI-2010-08227).

Spanish Scleroderma Group:

Norberto Ortego-Centeno, José Luis Callejas, and Raquel Rios, Systemic Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Clínico Universitario San Cecilio, Granada, Nura Navarrete and Antonio García, Department of Internal Medicine, Hospital Virgen de las Nieves, Granada, Antonio Fernández-Nebro, Department of Rheumatology, Hospital Carlos Haya, Málaga, María F. González-Estrubano, Department of Immunology, Hospital Virgen del Rocio, Sevilla; Julio Sánchez-Román and Mª Jesús Castillo, Department of Internal Medicine, Hospital Virgen del Rocio, Sevilla; Mª Ángeles Aguiné and Inmaculada Gómez-Gracia, Department of Rheumatology, Hospital Reina Sofía, Córdoba; Benjamin Fernández-Gutierrez and Luis Rodríguez-Rodriguez, Department of Rheumatology, Hospital Clínico San Carlos, Madrid; Esther Vicente, Department of Rheumatology, Hospital La Princesa, Madrid; Mónica Fernández Castro and José Luis Andreu, Department of Rheumatology, Hospital Puerta del Hierro, Madrid; Paloma García de la Peña, Department of Rheumatology, Hospital Universitario Madrid Norte Sanchinarro, Madrid; Francisco Javier López-Longo and Lina Martínez-Estrupiñán, Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid; Anna Pros, Department of Rheumatology, Hospital Del Mar, 08003 Barcelona; Vicente Fonollola, Department of Internal Medicine, Hospital Valle de Hebrón, Barcelona, Carlos Tolosa, Department of Internal Medicine, Hospital Parc Taulí, Sabadell; Mónica Rodríguez Carballera, Department of Internal Medicine, Hospital Universitari Mutua Terrassa, Barcelona; Elena Castellví, Unidad de Reumatología, Hospital de Internal Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona; Francisco Javier Navaréz, Department of Rheumatology, Hospital Universitari de Bellvitge, Barcelona; Francisco Javier Blanco-García, Natividad Oreo, and María Ángeles Robles, Department of Rheumatology, INIBIC–Hospital Universitario A Coruña; A Coruña; María-Victoria Egurbide, Department of Internal Medicine, Hospital de Cruces, Vizcaya; Luis Sáez-Comet, Systemic Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitario Miguel Servet, Zaragoza; Ricardo Blanco, Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander; Bernardino Díaz and Luis Traipella, Department of Internal Medicine, Hospital Central de Asturias, Oviedo; Federico Díaz and Vanesa Hernández, Department of Rheumatology, Hospital Universitario de Canarias, Tenerife; Emma Beltrán, Department of Rheumatology, Hospital del Doctor Peset Alexandre, Valencia, and José Andrés Román-Ivorra, Department of Rheumatology, Hospital Universitari i Politecnic La Fe, Valencia.

Author details

Instituto de Paratología y Biomedicina López-Neyra, IBLIN-CSIC, Avda. del Conocimiento s/n, 18010, Granada, Spain(Ammila) (Granada), Spain.

1Department of Internal Medicine, Hospital Carlos Haya, Avda Carlos Haya s/n 29010 Málaga, Spain.

2Department of Rheumatology, Hospital Virgen de la Victoria, Campus de Teatinos s/n 29010 Málaga, Spain.

3Department of Rheumatology, Hospital Universitario de Canarias, Ctra. Cuesta-Taco, s/n 38320, La Cuesta, San Cristóbal de La Laguna, Tenerife, Canarias, Spain.

4Department of Internal Medicine, Hospital Central de Asturias, Celestino Villamil, s/n 33006 Oviedo, Spain.

5Department of Autoimmune Diseases, Hospital Clinic, Carrer de Villarroel, 170 08036 Barcelona, Spain.

6Department of Rheumatology Unit and Chair, Spedali Civili, Università degli Studi, Piazzale Aldo Moro 2, 25123 Brescia, Italy.

7Department of Medicine, Policlinico GB Rossi, Università degli studi di Verona, Via dell’Artiglierie, 8 37129 Verona, Italy.

8Department of Rheumatology and Clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Charitéplatz 1, 10117 Berlin, Germany.

9Clinic for Immunology and Rheumatology Medical School, Carl-Neuberg-Str, 1 30625, Hannover, Germany.

10Department of Dermatology, University of Cologne, Kerpener Str 62, 50924 Köln, Germany.

11Department of Dermatology, Allergology, and Venereology, Ruhr University of Bochum, Steepeler Straße 129 44801 Bochum, Germany.

12Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Schillerstraße 1 91054 Erlangen, Germany.

13Section Complex Genetics, Department of Medical Genetics, University Medicine Center Utrecht, Universiteitsweg Stratum 3508 AB, Utrecht, The Netherlands.

14Department of Rheumatology, VU University Medical Center, De Boelelaan 1117 1081 HZ Amsterdam, The Netherlands.

15Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2 2300 RC, Leiden, The Netherlands.

16Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IFIAMV, Avda. Valdecilla, 25, 39008 Santander, Spain.

17Department of Rheumatology and Clinical Immunology, University Utrecht Medical Center, Universiteitsweg 100 Stratum 3508 AB, Utrecht, The Netherlands.

Authors’ contributions

MT and JM made substantial contributions to conception, design of study, and interpretation of data. MT carried out genotyping, analysis of data, and drafted the manuscript. CPS, JB, MCV, PC, MTC, RGP, EDF, MG, GE, LB, PA, CI, GR, TW, TK, AK, JHWD, NH, BPK, AEV, AJ, AJUS, MAGG, TRDRJ, and SSG had been involved in the acquisition of clinical data of the patients included in this study as well as the interpretation of the data. JM has been involved in revising of the final manuscript. All authors gave final approval of the version to be published.

Competing interests

The authors declare that they have no competing interests.

Received: 16 March 2012 Revised: 23 May 2012 Accepted: 25 June 2012 Published: 25 June 2012

References

1. Gabrielli A, Avvedimento EV, Krieg T: Scleroderma. N Engl J Med 2009, 360:1899-2003.

2. Martin J, Bossini-Castillo L, Martin J: Unraveling the genetic component of systemic sclerosis. Hum Genet 2012, 131:1023-1037.

3. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Nollie RJ: Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009, 229:152-172.

4. Peters AL, Stunz LL, Bishop GA: CD40 and autoimmunity: the dark side of a great activator. Semin Immunol 2009, 21:290-300.

5. Valakalanka RR, Woo C, Kirou KA, Kathy M, Berger D, Crow MK: Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 1999, 42:871-881.

6. Tamura N, Kobayashi S, Kato K, Bando H, Haruta K, Oyanagi M, Kuriyama M, Kippis TJ, Hashimoto H: Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol 2001, 28:2583-2590.

7. Faure GC, Benoist-Leguivaux D, Bene MC, Aubert V, Leclerc J: Coexpression of CD40 and class II antigens in Graves’ disease thyroid epithelial cells. Clin Immunol Immunopathol 1997, 84:212-215.
22. Citores MJ, Rua-Figueroa I, Rodriguez-Gallego C, Durantez A, Garcia-Martin-Donaire T, Losada-Fernandez I, Perez-Chacon G, Rua-Figueroa I, Vazgiourakis VM, Zervou MI, Choulaki C, Bertsias G, Melissourgaki M, Blanco-Kelly F, Matesanz F, Alcina A, Teruel M, Díaz-Gallo LM, Gómez-Laorden MI, Rodriguez-Lozano C, Rodriguez-Perez JC, Vargas JA, Perez-Aciego P:

8. Allanore Y, Borderie D, Meune C, Lemarechal H, Weber S, Bkianjog DJ, Khan A: Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Arthritis Rheum 2005, 64:481-483.

21. Komura K, Fujimoto M, Matsuhashi T, Yanaka K, Kodera M, Kawaij A, Hasegawa M, Takehara K, Sato S: Increased serum soluble CD40 levels in patients with systemic sclerosis. J Rheumatol 2007, 34:353-358.

18. Fukasawa C, Kogawag Y, Hargai M, Suguiro T, Takagi K, Kawamura M, Hara M, Kamatani N: Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 2003, 33:2700-2706.

15. Jacobson EM, Conception E, Oashi T, Tomer Y: A Graves’ disease–associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathogenesis. Endocrinology 2005, 146:2684-2691.

12. ANZgene: Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 2009, 41:824-828.

10. Fukasawa C, Kawaguchi Y, Harigai M, Sugiura T, Takagi K, Kawamoto M, Hasegawa M, Takehara K, Sato S: Increased serum soluble CD40 levels in patients with systemic sclerosis. J Rheumatol 2007, 34:353-358.

8. Allanore Y, Borderie D, Meune C, Lemarechal H, Weber S, Bkianjog DJ, Khan A: Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Arthritis Rheum 2005, 64:481-483.

21. Komura K, Fujimoto M, Matsuhashi T, Yanaka K, Kodera M, Kawaij A, Hasegawa M, Takehara K, Sato S: Increased serum soluble CD40 levels in patients with systemic sclerosis. J Rheumatol 2007, 34:353-358.